News
CNTA
40.50
0.00%
0.00
*News On Centessa Pharmaceuticals PLC ADR (CNTA) Now Under LLY
Dow Jones · 06/24 21:08
Centessa Pharmaceuticals Completes Acquisition by Eli Lilly Subsidiary
TipRanks · 06/24 13:17
Eli Lilly's $7.8 Bln Acquisition Deal Of Centessa Pharma Receives High Court Approval
NASDAQ · 06/23 06:29
Centessa announces High Court approval for acquisition by Eli Lilly
TipRanks · 06/22 20:30
Centessa Pharmaceuticals' Proposed $38/Share Acquisition By Eli Lilly Receives High Court Of Justice Of England And Wales Approval
Benzinga · 06/22 20:08
Weekly Report: what happened at CNTA last week (0615-0619)?
Weekly Report · 06/22 10:25
Weekly Report: what happened at CNTA last week (0608-0612)?
Weekly Report · 06/15 10:26
Centessa Shareholders Approve Eli Lilly Acquisition Scheme
TipRanks · 06/12 22:32
Weekly Report: what happened at CNTA last week (0601-0605)?
Weekly Report · 06/08 10:21
Catalyst Watch: SpaceX IPO, Apple's WWDC, CPI, and the World Cup kicks off
Seeking Alpha · 06/05 19:00
Centessa gets FDA orphan drug designation for cleminorexton
TipRanks · 06/04 19:00
Assessing Centessa Pharmaceuticals (CNTA) Valuation After Strong Multi Period Share Price Gains
Simply Wall St · 06/04 01:16
Centessa Advances Late-Stage Narcolepsy Trial With Orexin-Mimic Cleminorexton
TipRanks · 06/03 16:32
Weekly Report: what happened at CNTA last week (0525-0529)?
Weekly Report · 06/01 10:26
Weekly Report: what happened at CNTA last week (0518-0522)?
Weekly Report · 05/25 10:30
Centessa Advances Lilly Acquisition After Key Antitrust Clearance
TipRanks · 05/22 22:08
Weekly Report: what happened at CNTA last week (0511-0515)?
Weekly Report · 05/18 10:29
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA) and Radnet (RDNT)
TipRanks · 05/11 12:40
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
Barchart · 05/11 11:43
Weekly Report: what happened at CNTA last week (0504-0508)?
Weekly Report · 05/11 10:26
More
Webull provides a variety of real-time CNTA stock news. You can receive the latest news about Centessa Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.